Elite Pharmaceuticals, Inc. last reported quarterly results on Aug 13, 2026, for Q1 FY2027 (the quarter ended Jun 30, 2026): revenue of $32.4 million (-19.5% year over year) and diluted EPS of $0.01. It usually reports 44–48 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 13, 2026.
Results for Q2 FY2027, the quarter ending around Sep 30, 2026. Expected on a Friday. Based on last year's release for the same quarter on Nov 14, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 44–48 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 13, 2026
44 days after quarter end
|
Q1 FY2027
ended Jun 30, 2026
|
32
-19.5%
|
6
+200.4%
|
0.01
+200.0%
|
|
Feb 17, 2026
48 days after quarter end
|
Q3 FY2026
ended Dec 31, 2025
|
32
+119.9%
|
19
+270.7%
|
0.01
+200.0%
|
|
Nov 14, 2025
45 days after quarter end
|
Q2 FY2026
ended Sep 30, 2025
|
36
+92.4%
|
14
+224.2%
|
0.01
+200.0%
|
|
Aug 14, 2025
45 days after quarter end
|
Q1 FY2026
ended Jun 30, 2025
|
40
+113.9%
|
-6
-1055.7%
|
-0.01
|
|
Feb 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Dec 31, 2024
|
14
-7.6%
|
-11
-1642.0%
|
-0.01
|
|
Nov 14, 2024
45 days after quarter end
|
Q2 FY2025
ended Sep 30, 2024
|
19
+33.4%
|
-11
-173.9%
|
-0.01
-200.0%
|
|
Jul 1, 2024
1 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
Feb 14, 2024
45 days after quarter end
|
—
ended Dec 31, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELTP (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- NJ
- Headquarters
- Northvale, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1053369
- Former names
- ELITE PHARMACEUTICALS INC /DE/ (until Feb 8, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.